Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers

A Jahn, A Rump, T J Widmann, C Heining, P Horak, B Hutter, N Paramasivam, S Uhrig, L Gieldon, S Drukewitz, A Kübler, M Bermudez, K Hackmann, J Porrmann, J Wagner, M Arlt, M Franke, J Fischer, Z Kowalzyk, D WilliamV Weth, S Oster, M Fröhlich, J Hüllein, C Valle González, S Kreutzfeldt, A Mock, C E Heilig, D B Lipka, L Möhrmann, D Hanf, V Teleanu, M Allgäuer, L Ruhnke, O Kutz, A Knurr, A Laßmann, V Endris, O Neumann, R Penzel, K Beck, D Richter, U Winter, S Wolf, K Pfütze, C Geörg, B Meißburger, I Buchhalter, M Augustin, B Klink*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers'. Together they form a unique fingerprint.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology